Traumatic brain injury (TBI), a form of acquired brain injury, occurs when a sudden trauma causes damage to the brain. TBI can result when the head suddenly and violently hits an object, or when an object pierces the skull and enters brain tissue. Symptoms of a TBI can be mild, moderate, or severe, depending on the extent of the damage to the brain. A person with a mild TBI may remain conscious or may experience a loss of consciousness for a few seconds or minutes. Other symptoms of mild TBI include headache, confusion, lightheadedness, dizziness, blurred vision or tired eyes, ringing in the ears, bad taste in the mouth, fatigue or lethargy, a change in sleep patterns, behavioral or mood changes, and trouble with memory, concentration, attention, or thinking.
DelveInsight’s, “Traumatic brain injuries Pipeline Insight, 2021” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Traumatic brain injuries pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request for Free Sample Report: https://www.delveinsight.com/sample-request/traumatic-brain-injury-tbi-pipeline-insight
Some of Traumatic brain injury Companies are:
- Vasopharm GmbH
- SanBio, Inc.
- Avid Radiopharmaceuticals
- Hope Biosciences
- Pinteon Therapeutics
- SanBio
- NeuroVive Pharmaceutical
- Cellvation
- NoNO Inc.
- Avanir Pharmaceuticals
- Hibernaid, Inc.
- Tetra Therapeutics
- CytoDyn
- Annovis Bio
- Abliva
- Therapeutic solutions
- Nyrada
- Ischemix
- Many Others
Request for Free Sample Report: https://www.delveinsight.com/sample-request/traumatic-brain-injury-tbi-pipeline-insight
DelveInsight’s Traumatic brain injury report covers around 50+ products under different phases of clinical development like
- Late-stage products (Phase II and Phase II/III)
- Mid-stage products (Phase II and Phase II/III)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Traumatic brain injury Key Products
- VAS203
- SB623
- Flortaucipir F18
- PNT001
- HB-adMSCs
- NeuroSTAT
- CEVA101
- TRPM7 Antagonist
- AVP-786
- BPN14770
- Leronlimab
- R-phenserine
- Mesenchymal stem cells
- Ciclosporin intravenous
- And Many Others
Request for Free Sample Report: https://www.delveinsight.com/sample-request/traumatic-brain-injury-tbi-pipeline-insight
Current Traumatic brain injury Treatment Scenario and Traumatic brain injury Emerging Therapies:
- How many companies are developing Traumatic brain injury drugs?
- How many Traumatic brain injury drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Traumatic brain injury?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Traumatic brain injury therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Traumatic brain injury and their status?
- What are the key designations that have been granted to the emerging drugs?
Request for Free Sample Report: https://www.delveinsight.com/sample-request/traumatic-brain-injury-tbi-pipeline-insight
Table of Contents:
Introduction
Executive Summary
Traumatic brain injuries: Overview
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
Traumatic brain injuries – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Traumatic brain injuries companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Traumatic brain injuries Collaboration Deals
Late Stage Products (Phase III)
• Comparative Analysis
VAS203: Vasopharm
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
SB263: SanBio
Drug profiles in the detailed report…..
Early stage products (Phase I/II)
• Comparative Analysis
HB-adMSCs: Hope Biosciences
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Traumatic brain injuries Key Companies
Traumatic brain injuries Key Products
Traumatic brain injuries- Unmet Needs
Traumatic brain injuries- Market Drivers and Barriers
Traumatic brain injuries- Future Perspectives and Conclusion
Traumatic brain injuries Analyst Views
Traumatic brain injuries Key Companies
Appendix
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/traumatic-brain-injury-tbi-pipeline-insight